Literature DB >> 27586875

Schwannoma of the trochlear nerve-an illustrated case series and a systematic review of management.

Nurhan Torun1, Yosef Laviv2, Kianush Karimian Jazi2, Anand Mahadevan3, Rafeeque A Bhadelia4, Anderson Matthew5, Mitchell Strominger6, Ekkehard M Kasper7,8.   

Abstract

Schwannomas of cranial nerves in the absence of systemic neurofibromatosis are relatively rare. Among these, schwannomas of the trochlear nerve are even less common. They can be found incidentally or when they cause diplopia or other significant neurological deficits. Treatment options include observation only, neuro-ophthalmological intervention, and/or neurosurgical management via resection or sterotactic radiosurgery (SRS). In recent years, the latter has become an attractive therapeutic tool for a number of benign skull base neoplasm including a small number of reports on its successful use for trochlear Schwannomas. However, no treatment algorithm for the management of these tumors has been proposed so far. The goal of this manuscript is to illustrate a case series of this rare entity and to suggest a rational treatment algorithm for trochlear schwannomas, based on our institutional experience of recent cases, and a pertinent review of the literature. Including our series of 5 cases, a total of 85 cases reporting on the management of trochlear schwannomas have been published. Of those reported, less than half (40 %) of patients underwent surgical resection, whereas the remainder were managed conservatively or with SRS. Seventy-six percent (65/85) of the entire cohort presented with diplopia, which was the solitary symptom in over half of the cases (n = 39). All patients who presented with symptoms other than diplopia or headaches as solitary symptoms underwent surgical resection. Patients in the non-surgical group were mostly male (M/F = 3.5:1), presented at an older age and had shorter mean diameter (4.6 vs. 30.4 mm, p < 0.0001) when compared to the surgical group. Twelve patients in the entire cohort were treated with SRS, none of whom had undergone surgical resection before or after radiation treatment. Trochlear schwannoma patients without systemic neurofibromatosis are rare and infrequently reported in the literature. Of those, patients harboring symptomatic trochlear Schwannomas do not form a single homogenous group, but fall into two rather distinct subgroups regarding demographics and clinical characteristics. Among those patients in need of intervention, open microsurgical resection as well as less invasive treatment options exist, which all aim at safe relief of symptoms and prevention of progression. Both open microsurgical removal as well as SRS can achieve good long-term local control. Consequently, a tailored multidisciplinary treatment algorithm, based on the individual presentation and tumor configuration, is proposed.

Entities:  

Keywords:  Diplopia; Schwannoma; Trochlear nerve

Mesh:

Year:  2016        PMID: 27586875     DOI: 10.1007/s10143-016-0783-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  45 in total

1.  Schwannoma in patients with isolated unilateral trochlear nerve palsy.

Authors:  A S Feinberg; N J Newman
Journal:  Am J Ophthalmol       Date:  1999-02       Impact factor: 5.258

2.  Isolated schwannoma of the fourth cranial nerve: case report.

Authors:  R S Maurice-Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

3.  Trochlear neurinoma.

Authors:  M Yamamoto; M Jimbo; M Ide; O Kubo
Journal:  Surg Neurol       Date:  1987-10

4.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

Review 5.  Trochlear nerve schwannomas occurring in patients without neurofibromatosis: case report and review of the literature.

Authors:  S Santoreneos; A Hanieh; R E Jorgensen
Journal:  Neurosurgery       Date:  1997-07       Impact factor: 4.654

Review 6.  Trochlear nerve schwannoma removed by combined petrosal approach.

Authors:  E F Shenouda; A Ghosh; H B Coakham
Journal:  Br J Neurosurg       Date:  2002-12       Impact factor: 1.596

7.  Toward dose optimization for fractionated stereotactic radiotherapy for acoustic neuromas: comparison of two dose cohorts.

Authors:  David W Andrews; Maria Werner-Wasik; Robert B Den; Sun Ha Paek; Beverly Downes-Phillips; Thomas O Willcox; Greg Bednarz; Mitchell Maltenfort; James J Evans; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-29       Impact factor: 7.038

8.  Cystic trochlear nerve neurinoma mimicking intrinsic brainstem tumour.

Authors:  S N Shenoy; A Raja
Journal:  Br J Neurosurg       Date:  2004-04       Impact factor: 1.596

9.  Radiosurgery as definitive management of intracranial meningiomas.

Authors:  Douglas Kondziolka; David Mathieu; L Dade Lunsford; Juan J Martin; Ricky Madhok; Ajay Niranjan; John C Flickinger
Journal:  Neurosurgery       Date:  2008-01       Impact factor: 4.654

10.  The middle fossa approach for the removal of a trochlear schwannoma.

Authors:  Andrew B Boucher; L Madison Michael
Journal:  Case Rep Neurol Med       Date:  2014-03-12
View more
  2 in total

1.  Management of non-vestibular schwannomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section. Part I: oculomotor and other rare non-vestibular schwannomas (I, II, III, IV, VI).

Authors:  Jarnail Bal; Michael Bruneau; Moncef Berhouma; Jan F Cornelius; Luigi M Cavallo; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Torstein R Meling; Mahmoud Messerer; Pierre-Hugues Roche; Henry W S Schroeder; Marcos Tatagiba; Idoya Zazpe; Dimitrios Paraskevopoulos
Journal:  Acta Neurochir (Wien)       Date:  2021-11-09       Impact factor: 2.216

Review 2.  Trends in the Management of Non-Vestibular Skull Base and Intracranial Schwannomas.

Authors:  Carlos Suárez; Fernando López; William M Mendenhall; Simon Andreasen; Lauge Hjorth Mikkelsen; Johannes A Langendijk; Stefano Bondi; Juan P Rodrigo; Leif Bäck; Antti A Mäkitie; Verónica Fernández-Alvarez; Andrés Coca-Pelaz; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.